Synapse - Shanu Modi

Results (265)

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

Meeting Abstract

Beeram, M.; Krop, I.; Modi, S.; Tolcher, A.; Rabbee, N.; Girish, S.; Tibbitts, J.; Holden, S.; Lutzker, S.; Burris, H.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial

Meeting Abstract

Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
Breast Cancer Research and Treatment (2007)

Fulltext@MSK | Save

A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer

Meeting Abstract

Krop, I. E.; Beeram, M.; Modi, S.; Rabbee, N.; Girish, S.; Tibbitts, J.; Holden, S. N.; Lutzker, S. G.; Burris, H. A.
EJC Supplements (2007)

Fulltext@MSK | Save

A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer

Meeting Abstract

Krop, I. E.; Beeram, M.; Modi, S.; Rabbee, N.; Girish, S.; Tibbitts, J.; Holden, S. N.; Lutzker, S. G.; Burris, H. A.
Breast Cancer Research and Treatment (2007)

Fulltext@MSK | Save

Trastuzumab-MCC-DM1 (Tmab-MCC-DM1), a first-in-class HER2 antibody-drug conjugate (ADC) - A phase I study in patients (pts) with HER2+ metastatic breast cancer (BC)

Meeting Abstract

Beeram, M.; Krop, I. E.; Modi, S.; Tolcher, A. W.; Tibbitts, J.; Rabbees, N.; Girish, S.; Lutzker, S. G.; Holden, S. N.; Burris, H. A.
Annals of Oncology (2007)

Fulltext@MSK | Save

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study